Pharma BD Deal Intelligence
Teva's $6.8B all-cash acquisition of Cephalon bought specialty pharma scale but delivered a mixed result—outcome scoring lands it "Partially Achieved," with financial return and integration both scored weak (45/100 and 40/100) against a stronger strategic-fit rationale (70/100).
Teva / Cephalon: Partially Achieved (Score: 52/100)
Full analysis, sources & comparables →Teva acquired Cephalon for $6.8B, a specialty pharmaceutical company.
The FTC required Teva to sell rights to generic cancer pain drug and generic muscle relaxant as conditions of the $6.8 billion acquisition of Cephalon,…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Teva acquired Cephalon for $6.8B, a specialty pharmaceutical company.
Teva / Cephalon: Partially Achieved (Score: 52/100)
Assessment window: 5yr post-close.
70M US cases/yr · $5.0B US CNS Specialty Market (2011) · $1.1B Provigil US Revenue (2010)
Cephalon was a specialty pharma company known for Provigil (modafinil, $1.1B revenue) and pain medications. Teva's $6.8B acquisition combined the world's largest generic company with a branded CNS/oncology/pain portfolio and 30+ late-stage pipeline.
Provigil faced generic competition in 2012 (FTC mandate). Nuvigil served as successor but never matched Provigil sales. Treanda (bendamustine) became a key oncology asset. Teva later faced financial challenges from over-leveraged M&A.
Teva Pharmaceutical Industries closes acquisition/merger of Cephalon Inc. for $6.8B, establishing strategic position and initiating integration.
Strategic Fit: 70/100 | Financial Return: 45/100 | Pipeline Outcome: 45/100 | Integration: 40/100 | Deal Difficulty: 65/100. Partially Achieved overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Cephalon Inc. (this deal) | 2011 | $6.8B | 46 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
← Browse all deals · How we score deals
More: 2011 deals · Teva Pharmaceutical Industries Ltd. deals · Neurology deals